Skip to content
Medical Health Aged Care

Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

Tilray Brands, Inc. 4 mins read

New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG

COLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its medical cannabis division, Tilray Medical, the global leader in medical cannabis, enthusiastically welcomes the opening of the German medical cannabis market and the positive paradigm shift in German drug policy. Today’s landmark passage of the German Medical Cannabis Act represents a significant step forward and puts public health in the spotlight while providing patients with easier access to high-quality cannabis medicines produced in Germany.

Tilray Medical's Chief Strategy Officer and Head of International Denise Faltischek comments: "The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs. Facilitating access to the highest quality cannabis medicines through the new Medical Cannabis Act, produced in Germany, will help to improve patient care and provide patients with a wider range of treatment options."

Tilray Medical looks forward to working with numerous partners to utilize the production capacity at Tilray’s state of the art Neumünster site, which is one of only three cannabis cultivation facilities located in Germany, in order to ensure that patients have improved access to the highest quality cannabis medicines grown in Germany.

As a leader in the field of medical cannabis research and production, Tilray Medical strongly believes that these developments will have a positive impact on the health and well-being of many patients in Germany. We look forward to exploring the path opended by the German government and all stakeholders in promoting improved access to medical cannabis, and the opportunity to optimize care for our patients.

About Tilray Medical  

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in over 20 countries and across five continents. 

Further information can also be found at www.tilraymedical.de

About Tilray Brands 

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Tilray’s mission is to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.  

For more information on how we open a world of wellbeing, visit, Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information:
Media: Berrin Noorata, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com


Primary Logo

More from this category

  • Medical Health Aged Care
  • 18/07/2024
  • 00:00
Dementia Australia

100,000 people worldwide have downloaded BrainTrack – have you?

More than 100,000 people worldwide have downloaded BrainTrack, the multi-award-winning free app supporting people to take a positive step forward in their brain health. Since its release in October 2022 BrainTrack has been downloaded across 202 countries including Australia, India and the United States. BrainTrack, a Dementia Australia initiative, helps people privately monitor and better understand potential changes in their cognition over time through fun, travel-themed games that have been adapted from validated cognitive testing. Users can share their results with their doctor to support the early identification of cognitive changes that may warrant further testing. Dementia Australia ExecutiveDirectorServices,AdvocacyandResearch Dr…

  • Medical Health Aged Care, Science
  • 17/07/2024
  • 14:00
De Motu Cordis

De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product

Brisbane, QLD – 17 July 2024 – De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion plans encompass services from drug product manufacturing and device assembly through to commercial launch of DMC’s product, DMC-IH1. DMC-IH1 is an inhaled epinephrine drug-device combination product being developed for the treatment of anaphylaxis using a dry powder inhaler (DPI). Catalent DPI drug delivery services offer end-to-end solutions to bring customers through the entire clinical pharma journey by leveraging the commercial…

  • Medical Health Aged Care, Women
  • 17/07/2024
  • 07:00
Monash University

Study underlines the importance of supporting primary care clinicians to deliver early medical abortion and long acting reversible contraception

The impetus for additional support and training for clinicians wanting to deliver important sexual and reproductive services has received a boost with the release of Monash University-led research. Published in BMJ – Sexual and Reproductive Health, the AusCAPPS study found that GPs, nurses and pharmacists seek peer support and online resources to deliver long-acting reversible contraception (LARC) and early medical abortion (EMA) in Australian primary care.Experienced and emerging providers of LARC and EMA sought support regarding clinical issues online from AusCAPPS, which is the Australian Contraception and Abortion Primary Care Practitioner Support Network, an evidence-based virtual community of practice launched…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.